期刊文献+

辅助治疗对高级别胶质瘤复发时间的影响 被引量:1

Effects of adjunctive therapies of high-grade glioma on delaying recurrence time
下载PDF
导出
摘要 目的分析高级别胶质瘤术后辅助治疗(伽玛刀、常规分割放射治疗、化疗以及同步放化疗)对其平均复发时间的影响。评估辅助治疗对高级别胶质瘤的临床疗效。方法收集德阳市人民医院神经外科2008年1月~2013年12月间收治的具有完整病历资料的高级别脑胶质瘤复发患者64例。分为28例单纯手术治疗患者(A组);36例行辅助治疗患者(B组)包括:10例术后行伽玛刀治疗患者(Ⅰ组);4例术后行常规分割放射治疗患者(Ⅱ组);3例术后行化疗患者(Ⅲ组);19例术后行同步放化疗患者(Ⅳ组)。分析不同组别平均复发时间。结果 A组平均复发时间为7.804个月;B组平均复发时间为13.431个月;Ⅰ组平均复查时间为11.450个月;Ⅱ组平均复发时间为8.000个月;Ⅲ组平均复发时间为13.167个月;Ⅳ组平均复发时间为15.659个月。A组与B组及Ⅳ组之间有统计学差异。A组与Ⅰ组、Ⅱ组及Ⅲ组间无统计学差异。结论同步放化疗对高级别胶质瘤的平均复发时间有一定延缓作用。 Objective To investigate the effects of postoperative concomitant therapies of highgrade glioma(gamma knife, radiotherapy, chemotherapy, synchronization chemoradiation) on delaying median relapse time and assess the clinical significance of postoperative concomitant therapy. Methods Sixty-four patients with recurring high-grade glioma patients in Deyang People's Hospital between Jan2008 to Dec 2013 were included in the study. Of them, 28 patients were treated with only operation(A group), 36 patients treated with postoperative concomitant therapy(B group). In B group, 10 patients were treated with postoperative gamma knife(I group), 4 patients received postoperative radiotherapy(Ⅱ group), 3 patients received postoperative chemotherapy(Ⅲ group), 19 patients were treated with postoperative synchronization chemoradiation(Ⅳ group). Analyse the median relapse time among the groups. Results The median relapse time is 7.804 months in A group, 13.431 months in B group; 11.450 months in Ⅰ group, 8.000 months in Ⅱ group; 13.167 months in Ⅲgroup, 15.659 months in Ⅳ group. It has statistical significance between A group and B group, also between A group and Ⅳ group. But it has no statistical significance among A group and other groups.Conclusion Synchronization chemoradiation is effective for postponing median relapse time of Highgrade glioma.
出处 《岭南现代临床外科》 2015年第2期172-174,共3页 Lingnan Modern Clinics in Surgery
关键词 胶质瘤 手术 放疗 化疗 伽玛刀 Glioma Operation Radiotherapy Chemotherapy Gamma knife
  • 相关文献

参考文献3

二级参考文献25

  • 1曹永珍,姜炜,吕仲虹.143例脑胶质瘤立体定向加常规放疗的疗效观察[J].中华放射肿瘤学杂志,2006,15(5):375-378. 被引量:24
  • 2邓万凯,黄书岚.恶性胶质瘤术后应用替莫唑胺化疗联合放疗的临床观察[J].肿瘤防治研究,2006,33(10):758-760. 被引量:14
  • 3黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 4Naravan NA, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results [ J ]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 892- 897.
  • 5Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy [J]. Cancer, 2002, 94(5): 1593-1611.
  • 6Chakravarti A, Berkey B, Robins HI, et al. An update of phase I / II study of gefitinib with radiotherapy in newly diagnosed glioblastoma[J].J Clin Oncol, 2006, 24(18suppl): 1527.
  • 7Brown PD, Krishnan S, Sarkaria JN, et al. Phase I /II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma muhiforme: North Central Cancer Treatment Group Study N0177 [ J ] . J Clin Oneol, 2008,26(34): 5603-5609.
  • 8Tania CR, Javier F, Mauricio C, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor(EGFR) antibody h-R3: Report from a phase I /II trial [ J ] . Cancer Biol Ther, 2006, 5(4): 375-379.
  • 9Stephanie E, Combs MN, Lutz E, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of- care postoperative radiation alone in patients with WHO grade Ⅲ astrocytic tumors [ J ] . Radiother Oncol, 2008, 88(2): 177-182.
  • 10Stupp R, Waren P. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].N Engl J Med, 2005, 352(10): 987-996.

共引文献36

同被引文献4

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部